Mederi Therapeutics, Inc., manufacturers of Stretta Therapy for GERD, today announced that a new study, published in Managed Care, suggests the potential for substantial payer cost savings associated with radiofrequency energy (RFE) treatment of GERD patients, as compared to treatment with medical management or fundoplication.

Stretta clinical data presented at DDW2016 shows effectiveness in challenging GERD patient populations: Obese patients, laryngopharyngeal reflux (LPR) symptoms, GERD post-nissen. DDW activities also included the launch of the new Stretta RFT3 system and four presentations by international Stretta expert physicians.

Mederi Therapeutics today announced a new multi-center registry that will study the benefit of Stretta Therapy as a treatment option in patients who experience gastroesophageal reflux disease (GERD) after sleeve gastrectomy (SG).

Get #GERDSmart! It's time to Get Smart About GERD and help spread the word about the link between chronic reflux and Esophageal Cancer!

Stretta Therapy, a non-ablative radiofrequency treatment for GERD, was called "effective, safe and durable following 15 years of worldwide use" and cited as a "viable complement or alternative to medical and surgical treatment" in a newly-published clinical review of endoscopic techniques for gastroesophageal reflux disease (GERD). Authors Wai-Kit Lo, MD, MPH and Hiroshi Mashimo, MD, PhD of Harvard Medical School, examined multiple alternatives to PPI therapy or surgery, including Stretta and other devices such as endoscopic plication and suturing, as well as injectable and implantable bulking agents. Their findings have been published in the Journal of Clinical Gastroenterology.